Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. AMZN
7. USO
8. TLT
9. BETR
10. LEN

Go back to Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors
AGIOS PHARM (NASDAQ: AGIO) Delayed: 33.63 +0.68 (2.06%)
Previous Close $32.95    52 Week High $71.49 
Open $33.42    52 Week Low $33.50 
Day High $34.30    P/E N/A 
Day Low $33.19    EPS $-1.18 
Volume 212,747